The Pentagon’s updated 1260H list, which now includes roughly two dozen new Chinese entities, effectively bars firms from conducting business with the U.S. military. WuXi AppTec, which provides contract research and manufacturing services for global giants such as Eli Lilly and Johnson & Johnson, responded by labeling the designation a mistake. The company stated it will take immediate action to challenge the classification.

While the news rattled market sentiment, analysts suggest the operational impact may remain limited. Nomura’s Jialin Zhang noted that revenue derived from U.S. defense procurement is negligible for the drugmaker, and Jefferies’ Cui Cui highlighted that multinational pharmaceutical firms continue to prioritize cost efficiency by utilizing Chinese manufacturing hubs. Despite the volatility, experts maintain that the company’s core business model and deep integration into the global drug development supply chain provide a significant buffer against long-term disruption.